1004618-77-2Relevant academic research and scientific papers
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 00803; 0010-0012, (2021/06/26)
The present invention provides compounds, compositions thereof, and methods of using the same.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 00548-00549, (2021/08/13)
The present invention provides compounds, compositions thereof, and methods of using the same.
CRYSTALLINE FORMS OF IRAK DEGRADERS
-
Paragraph 0004, (2021/12/28)
The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation and uses of the same in the tr
DEUTERATED IRAK DEGRADERS AND USES THEREOF
-
Paragraph 00426; 00443-00445, (2021/12/12)
The present invention provides deuterium-enriched compounds, compositions thereof, and methods of using the same.
MDM2 DEGRADERS AND USES THEREOF
-
Paragraph 00791; 00792-00793, (2021/09/26)
The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.
PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF
-
Page/Page column 187, (2021/06/26)
Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 00962; 001145-001147, (2020/06/19)
The present invention provides compounds, compositions thereof, and methods of using the same.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 00794; 00816-00818, (2021/01/23)
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 00290; 001170-001172, (2021/01/23)
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 2881; 2882, (2019/07/10)
The present invention provides compounds, compositions thereof, and methods of using the same.
